Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Natural History of Clostridioides Difficile Infection

NCT04801862 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitario de Valme
Phase
Observational
Started
2021-01-01
Last updated
2026-09-17

Condition(s) studied

Clostridium Difficile InfectionHealth Care Associated InfectionNosocomial Infection

Study summary

Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI). To generate a predictive tool based on epidemiological, clinical, genetic and microbiologic variables aimed to identify patients at a higher risk of CDI recurrence in a context of optimized ICD management. Design: Multicenter prospective cohort study. Patients: Older than 18 years patients with CDI diagnosis, made by IDSA criteria, in the participant centers.

Follow-up: A stewarship program aimed to improve CDI management, including early detection of CDI recurrence, will be implemented in the participant centers. Blood samples for genetic testing and stool samples for intestinal microbiome studies will be collected.

Variables and data analysis: The primary outcome variable will be the emergence of CDI recurrence. Potential independent predictors of recurrence, including genetic and microbiological factors, will be assessed. A predictive tool based on independent predictors of recurrence will be built in a development subpopulation. The performance of the model will be assessed by ROC curves, and sensititvity, especificity, as well as negative and positive predictive values will be calculated, both in the development subpopulation and in a validation subset.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age older than 18 years * New episode of Clostridioides difficile infection, based on IDSA criteria. Exclusion Criteria: \- None

Primary outcome measure(s)

  • CDI recurrence — First 8 weeks after end of therapy
    Clostridioides difficile recurrence
  • CDI reinfection — Between 8 weeks after end of therapy and before 24 weeks
    New episode of Clostridioides difficile infection

Trial sites (15)

FacilityCityRegionStatus
Hospital Universitario San Juan Alicante Alicante Recruiting
Hospital Vega Baja Orihuela Alicante Recruiting
Hospital Marina Baixa Villajoyosa Alicante Recruiting
Hospital Universitario de Puerto Real Puerto Real Cadiz Terminated
Hospital Universitario San Cecilio Granada Granada Recruiting
Hospital Juan Ramón Jiménez Huelva Huelva Recruiting
Hospital Regional Universitario de Málaga Málaga Málaga Withdrawn
Hospital Universitario Virgen de la Victoria Málaga Málaga Recruiting
Consorcio Hospital General de Valencia Valencia Valencia Recruiting
Hospital Clínico Universitario de Valencia Valencia Valencia Recruiting
Hospital Politécnico Universitario La Fe de Valencia Valencia Valencia Recruiting
Hospital General Universitario de Alicante Alicante Spain Recruiting
Hospital Universitario Reina Sofía Córdoba Spain Terminated
Hospital Universitario de Valme Seville Spain Recruiting
Hospital Universitario Virgen Macarena Seville Spain Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04801862 on ClinicalTrials.gov ↗ ← All trials in Spain